REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-02-23

Reporting Person: VAGELOS P ROY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-23	Common Stock	M	1921	$52.03	Acquired	239009	Direct
2021-02-23	Common Stock	M	248079	$52.03	Acquired	487088	Direct
2021-02-23	Common Stock	F	137998	$458.48	Disposed	349090	Direct
2021-01-19	Common Stock	G	414	$0.0	Disposed	142796	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Incentive Stock Option (right to buy)	$52.03	M	1921	Disposed	2021-12-16	Common Stock (1921)	Direct
2021-02-23	Non-Qualified Stock Option (right to buy)	$52.03	M	248079	Disposed	2021-12-16	Common Stock (248079)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2214	Indirect
Common Stock	47786	Indirect
Common Stock	3609	Indirect

Footnotes

F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.

F2: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.